Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

被引：10
|
作者：
Zinzani, Pier Luigi
Delwail, Vincent
Paneesha, Shankara
Rule, Simon
Garcia-Sancho, Alejandro Martin
Marin-Niebla, Ana
Salles, Gilles
Sancho, Juan-Manuel
Vergote, Vibeke
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Mehta, Amitkumar
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134609
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [21] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [22] Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
    Trneny, Marek
    Avigdor, Abraham
    Mckinney, Matthew S.
    Paneesha, Shankara
    Wahlin, Bjorn E.
    Hrom, John S.
    Cunningham, David
    Morley, Nicholas
    Canales, Miguel
    Bastos-Oreiro, Mariana
    Belada, David
    Devizzi, Liliana
    Zheng, Fred
    Demarini, Douglas J.
    Jiang, Wei
    Jiang, Ping
    Lynch, Ryan C.
    ECLINICALMEDICINE, 2023, 63
  • [23] Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Rene-Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Covey, Todd
    Dua, Richa
    Hamdy, Ahmed
    Huang, Xin
    Izumi, Raquel
    Patel, Priti
    Slatter, J. Greg
    Jurczak, Wojciech
    BLOOD, 2017, 130
  • [24] A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma
    Martin, Peter
    Blum, Kristie
    Bartlett, Nancy L.
    Park, Steven I.
    Maddocks, Kami J.
    Ruan, Jia
    Di Liberto, Maurizio
    Huang, Xiangao
    Inghirami, Giorgio
    Harris, Pamela
    Chen-Kiang, Selina
    Leonard, John P.
    BLOOD, 2016, 128 (22)
  • [25] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [26] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
    Michael Wang
    Radhakrishnan Ramchandren
    Robert Chen
    Lionel Karlin
    Geoffrey Chong
    Wojciech Jurczak
    Ka Lung Wu
    Mark Bishton
    Graham P. Collins
    Paul Eliadis
    Frédéric Peyrade
    Yihua Lee
    Karl Eckert
    Jutta K. Neuenburg
    Constantine S. Tam
    Journal of Hematology & Oncology, 14
  • [27] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
    Wang, Michael
    Ramchandren, Radhakrishnan
    Chen, Robert
    Karlin, Lionel
    Chong, Geoffrey
    Jurczak, Wojciech
    Wu, Ka Lung
    Bishton, Mark
    Collins, Graham P.
    Eliadis, Paul
    Peyrade, Frederic
    Lee, Yihua
    Eckert, Karl
    Neuenburg, Jutta K.
    Tam, Constantine S.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [28] A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Qualls, David
    Lam, Hiu Ying
    Whiting, Karissa
    Kumar, Anita
    Matasar, Matthew
    Owens, Colette
    Nichols, Chelsea
    Espeleta, James A.
    Qiu, Annie
    Subzwari, Sarima
    Biggar, Erin
    Seshan, Venkatraman
    Salles, Gilles
    Younes, Anas
    Batlevi, Connie
    BLOOD ADVANCES, 2022, 6 (18) : 5262 - 5266
  • [29] PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME
    Rule, S.
    Wang, M. L.
    Martin, P.
    Auer, R.
    Kahl, B. S.
    Jurczak, W.
    Advani, R. H.
    Romaguera, J.
    Williams, M.
    Barrientos, J. C.
    Chmielowska, E.
    Radford, J. A.
    Stilgenbauer, S.
    Truong, V.
    Chang, M.
    Beaupre, D. M.
    Goy, A.
    Blum, K. A.
    HAEMATOLOGICA, 2014, 99 : 150 - 150
  • [30] Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).
    Coleman, Morton
    Belada, David
    Casasnovas, Rene-Olivier
    Gressin, Remy
    Lee, Hui-Peng
    Mehta, Amitkumar
    Munoz, Javier
    Verhoef, Gregor
    Corrado, Claudia
    DeMarini, Douglas James
    Zhao, Wanying
    Chen, Xuejun
    Fay, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345